Clinical trials: Type 1 Diabetes Mellitus (T1DM)
Type 1 Diabetes
Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.
- Trial name
- NCT00489645
- Testing
- pramlintide
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Type 1 Diabetes
Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM
This study is a prospective, single-center, parallel-design,1:1 randomized controlled trial with triple blinding. It aims to investigate the effects of fecal microbiota transplantation (FMT) on cognitive function in patients with…
- Trial name
- NCT06496412
- Testing
- fecal microbiota transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
T1DM, Hypersensitivity
The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series
Background Type 1 diabetes mellitus is a chronic metabolic disorder that presents a significant set of challenges to the patient, their family and the physician.
- Trial name
- NCT03594565
- Testing
- Fluticasone Propionate
- Volunteers
- 13 people
- Sponsor
- Assaf-Harofeh Medical Center
T1DM - Type 1 Diabetes Mellitus
Allogeneic Anti-CD7 CAR-T for Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and lifelong dependence on exogenous insulin.
- Trial name
- NCT07528105
- Testing
- Allogeneic CD7-Targeted CAR-T Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Zhongshan Hospital
Type 1 Diabetes Mellitus
Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Padova
A single arm, single treatment study is proposed to assess the feasibility of a portable artificial pancreas system outside of a hospital based clinical research center.
- Trial name
- HomeCTR1_2 (NCT01447992)
- Testing
- Portable artificial pancreas system with Control-To-Range
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- University of Virginia
Type 1 Diabetes Mellitis
Diathermy On Diabetes Glucose Monitoring Effectiveness
The goal of this observational study is to investigate if diathermy (a surgical tool that uses electrical energy to control bleeding) has any affect on the accuracy and functioning of continuous glucose monitoring systems in…
- Trial name
- DODGE (NCT07583238)
- Where
- United Kingdom
- Volunteers
- 126 people
- Sponsor
- University of Nottingham
Type 1 Diabetes Mellitus
Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System
In this protocol the investigators plan to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged…
- Trial name
- MDB005 (NCT01390259)
- Testing
- Open-Loop, Closed-Loop
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Virginia
Type1 Diabetes Mellitus
Chinese Smartphone App for 6-18 Years With T1DM - RCT
Moving into the era of electronic communication, it changes the way we shall engage our children and adolescents. According to data of the Census and Statistics Department of Hong Kong releases in 2019, more than 80% and up to…
- Trial name
- NCT05418569
- Testing
- Intervention arm - A new smartphone application for pediatric type 1 DM, Standard diabetic eduction
- Where
- Hong Kong
- Volunteers
- 114 people
- Sponsor
- Chinese University of Hong Kong
Type 1 Diabetes Mellitus, Type 1 Diabetes
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
- Trial name
- NCT00690066
- Testing
- PROCHYMAL®
- Where
- 20 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mesoblast, Inc.
T1DM - Type 1 Diabetes Mellitus
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
- Trial name
- NCT05908448
- Testing
- 13 CGM (continuous glucose monitor)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Sinocare
Diabetes Mellitus
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470
The purpose of this study is to investigate safety, tolerability, pharmacokinetics (PK) ad pharmacodynamics (PD) of HM12470 after single injection in T1DM and T2DM patients.
- Trial name
- NCT02302443
- Testing
- HM12470, Active comparator
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 1 Diabetes Mellitus
Incretin Axis in Type 1 Diabetes Mellitus
Type 1 diabetes is an autoimmune disorder characterized by beta cell destruction resulting in insulinopenia. Currently it is being treated with insulin. Dipeptidylpeptidase inhibitors (DPP4 inhibitors e.g.
- Trial name
- NCT02725502
- Testing
- Linagliptin
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Type 1 Diabetes Mellitus
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
The purpose of this study is to demonstrate the safety and feasibility of a decision support system aimed at reducing glucose variability in T1DM patient using an insulin pump.
- Trial name
- NCT02558491
- Testing
- Decision Support System, Usual Care
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Daniel Chernavvsky, MD
Type1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes.
- Trial name
- NCT03367390
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Insulin-Dependent
Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
- Trial name
- NCT00073255
- Testing
- hokt3g1 (ALA-ALA)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus (T1DM)
Pediatric Insulin Plan Calculator for T1DM Management
This is a multi-centre, prospective, randomized, open-label controlled trial designed to evaluate the effectiveness of a flexible digital insulin dose calculator in children under 12 years of age with Type 1 Diabetes Mellitus…
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus (T1DM), T1DM, T1DM - Type 1 Diabetes Mellitus
- Trial name
- FLEXI-T1D (NCT07427134)
- Testing
- Flexible Digital Insulin Dose Calculator
- Where
- 2 sites in Iraq, Pakistan
- Volunteers
- 440 people
- Sponsor
- Sultan Qaboos University
Type 1 Diabetes Mellitus
Immunotherapy with Autologous Tregs in T1DM
Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive immune distruction of pancreat beta cells and deterioration of endogenous insulin secretion.
- Trial name
- NCT06708780
- Testing
- Ex vivo Expanded Human Autologous Regulatory T Cells, Routine Care
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05210530
- Testing
- VCTX210A unit
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- CRISPR Therapeutics AG
Type 1 Diabetes Mellitus
A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM
This is a single centre, double-blind, randomised, three-period crossover phase 1 trial in subjects with type 1 diabetes mellitus (T1DM). Each subject will be randomly allocated to a sequence of three treatments, i.e.
- Trial name
- NCT03176524
- Testing
- BioChaperone® glucagon formulation 1, BioChaperone® glucagon formulation 2, GlucaGen® HypoKit®
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Adocia
Type 1 Diabetes
Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
This study will be an open-label, cross-over study as subjects will be studied under both study conditions - suspension of subcutaneous insulin infusion via pump during treatment with insulin alone (control) vs.
- Trial name
- NCT02673138
- Testing
- canagliflozin, basal interruption without canagliflozin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University